Tamiflu Sales Boost Roche Earnings, As Genentech Merger Is Defended
Roche executives were on the defensive about the effects of last year's acquisition of Genentech at a Feb. 4 meeting to discuss their 2009 financial results. And there was good reason
You may also be interested in...
Roche's novel interleukin-6 inhibitor Actemra won FDA approval Jan. 8 for second-line use in rheumatoid arthritis - after an FDA "complete response" letter set the product's regulatory process back more than a year
The hard task of integration—and the battle to retain Genentech employees—begins, while the DNA ticker symbol is up for grabs.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011